Investors are turning their attention to the hair loss treatment market, viewing it as the next major opportunity after the boom in GLP-1 weight-loss drugs. This shift is driven by the fact that pattern hair loss affects an estimated 50 million men and 30 million women in the US, with no new approved drugs since the late 1990s. The promise of novel treatments is attracting significant capital, similar to the consumer-driven market for obesity drugs.
Companies like Veradermics Inc. (trading as “MANE”) have seen their shares surge nearly 500% since going public in February, while Absci Corp.’s stock has more than doubled in 2026. Cosmo NV also reported positive results for an experimental male hair-loss treatment. Current options for those ineligible for or unable to afford hair transplant surgery include over-the-counter topical minoxidil (Rogaine) and prescription finasteride (Propecia), both of which have notable side effects, such as heart palpitations for minoxidil and reduced sex drive for finasteride. Analysts believe these new treatments will appeal to consumers willing to pay out-of-pocket for better alternatives.
Cosmo's topical medicine, clascoterone, is one of the closest to market, targeting the root cause of male-pattern hair loss by blocking a hormone directly at the hair follicle. The company plans to submit a new drug application to US regulators in the first quarter of 2027, and Jefferies analysts estimate its global sales could reach $3 billion, assuming a capable commercial partner is secured. Veradermics announced positive results for its tablet minoxidil formulation in male-pattern hair loss and promising mid-stage data for women, potentially becoming the first approved pill for female-pattern hair loss. Absci is developing an AI-designed shot, ABS-201, with interim data expected in the second half of this year.
Analysts are universally bullish on companies like Cosmo and Veradermics, anticipating that the market can accommodate multiple successful drugs. Jefferies analyst Roger Song, who has the highest price target on Veradermics, notes that many hair loss patients often use multiple treatments. OrbiMed’s Geoff Hsu, portfolio manager of the Biotech Growth Trust Plc, highlights that both obesity and hair loss are large consumer markets with significant revenue potential for safe and effective drugs. Despite the high risks associated with drug development, analysts remain optimistic about future gains, seeing these investments as potential "zero or hero" stories.
